Your browser doesn't support javascript.
loading
Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?
Habib, Samy L; Al-Obaidi, Noor Y; Nowacki, Maciej; Pietkun, Katarzyna; Zegarska, Barbara; Kloskowski, Tomasz; Zegarski, Wojciech; Drewa, Tomasz; Medina, Edward A; Zhao, Zhenze; Liang, Sitai.
Afiliação
  • Habib SL; Geriatric Research Education and Clinical Center, South Texas, Veterans Healthcare System; Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229, USA.
  • Al-Obaidi NY; Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229, USA.
  • Nowacki M; Collegium Medicum, Bydgoszcz and Nicolaus Copernicus University, Torun, Poland.
  • Pietkun K; Collegium Medicum, Bydgoszcz and Nicolaus Copernicus University, Torun, Poland.
  • Zegarska B; Collegium Medicum, Bydgoszcz and Nicolaus Copernicus University, Torun, Poland.
  • Kloskowski T; Collegium Medicum, Bydgoszcz and Nicolaus Copernicus University, Torun, Poland.
  • Zegarski W; Collegium Medicum, Bydgoszcz and Nicolaus Copernicus University, Torun, Poland.
  • Drewa T; Collegium Medicum, Bydgoszcz and Nicolaus Copernicus University, Torun, Poland.
  • Medina EA; Department of Pathology.
  • Zhao Z; Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229, USA.
  • Liang S; Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229, USA.
J Cancer ; 7(12): 1621-1631, 2016.
Article em En | MEDLINE | ID: mdl-27698899
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article